Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)
Seelos Therapeutics, Inc. (SEEL)
Last seelos therapeutics, inc. earnings: 5/21 05:12 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first subjects in a Phase I Drug-Drug Interaction (DDI) study, SLS-002-101. SLS-002-101 is a single-center, open-label study of SLS-002 dosed in combination with two commonly prescribed antidepressants. This study plans to enroll 48 healthy volunteers, studied over 14 days, randomized into two treatment arms and dosed with a combination of SLS-002 and either, venlafaxine ER or sertraline. The primary objective of this study is to evaluate the pharmacokinetic (PK) profile, DDI, and safety measures of SLS-002. “The initial dosing of SLS-002 is a very significant event for Seelos and in the development of intranasal racemic ketamine. We hope to initially demonstrate that SLS-002 can be safely dosed in combination with subjects’ cur
Show less
Read more
Impact Snapshot
Event Time:
SEEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SEEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SEEL alerts
High impacting Seelos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SEEL
News
- Seelos Announces Second Postponement of its Annual Meeting of StockholdersPR Newswire
- Seelos gets Nasdaq delisting notice Oct. 15, 2024 9:25 AM ET By: Preeti Singh , SA News Editor [Seeking Alpha]Seeking Alpha
- Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter MarketPR Newswire
- Seelos Therapeutics Announces 1-for-16 Reverse Stock SplitPR Newswire
- Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSDPR Newswire
SEEL
Sec Filings
- 11/22/24 - Form NT
- 11/22/24 - Form 8-K
- 11/14/24 - Form SC
- SEEL's page on the SEC website